FDA approves expanded label for Xarelto of Johnson & Johnson
The Food and Drug Administration permitted labelling of blood thinner, Xarelto of Johnson & Johnson, as it can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease (CAD or PAD). For these conditions, Xarelto (rivaroxaban tablets) is used in combination with aspirin. The call is taken on the basis of data from the Phase 3 COMPASS trial that indicated Xarelto with aspirin decreased stroke by 42%, cardiovascular death by 22% and heart attack by 14% compared with aspirin alone in this patient group.
Alnylam go slow on accelerated ...
